news
Bioavailability enhancement services market to exhibit 11 percent CAGR
Between 2022 and 2035, the bioavailability enhancement services market will see an 11 percent compound annual growth rate, a report has predicted.
List view / Grid view
Eurofins CDMO
video
On-demand webinar: Highway to clinic: Formulation strategies for improved bioavailability
With the appropriate formulation strategies, the challenges around poorly soluble compounds can indeed be overcome. Reducing development time and ultimately speeding up the route to market.
content_hub
Eurofins CDMO
22 March 2021 | By
Eurofins CDMO is a leading global Contract Development and Manufacturing Organization (CDMO) that provides clients with APIs / Drug Substance and Drug Product development for biologicals and small molecules. Science is our fondation and allows us to support small and major biopharmaceutical companies. Our sustainable and flexible methods help them…
news
Eurofins Alphora and Eurofins Amatsigroup announce company rebrand to Eurofins CDMO
The commercial brand for Eurofins Alphora and Eurofins Amatsigroup is now Eurofins CDMO (Contract Development Manufacturing Organization).
whitepaper
Flyer: API Development Services
Eurofins CDMO works closely with clients to provide phase-appropriate solutions to balance any immediate and long term API technology development needs.
whitepaper
Flyer: API commercialisation
Eurofins CDMO works closely with clients to provide phase-appropriate solutions to balance any immediate and long-term API technology development and commercialisation needs.
whitepaper
Flyer: Your drug development partner
Eurofins CDMO provides full range of drug development and manufacturing services from formulation screening and development, analytical development, stability studies and pre-clinical safety assessment studies to sterile and non-sterile manufacturing, IND/ IMPD and NDA/ CTD services, as well as clinical trial material including packaging and logistics.
whitepaper
Flyer: Biologicals drug substance and drug product
Eurofins CDMO provides a full suite of drug development services encompassing development of the bioprocesses, formulation screening, analytical development, pre-clinical testing, sterile and non-sterile bio-manufacturing of clinical trial batches and orphan drugs.
content_hub
Eurofins CDMO
23 January 2019 | By
Eurofins CDMO provides development & manufacturing services for your Drug Substance/API and Drug Product from early phases.
whitepaper
Flyer: Sterile manufacturing – finished dosage forms
Eurofins CDMO provides a wide range of aseptic processing services for all drug product configurations with flexibility to accommodate a wide range of compounds, primary packaging systems, batch sizes and fill volumes to help develop your Active Pharmaceutical Ingredient or bulk product into Finished Dosage Forms for use in clinical…
